These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34823541)

  • 21. Cancer Nanovaccines: Nanomaterials and Clinical Perspectives.
    Desai N; Chavda V; Singh TRR; Thorat ND; Vora LK
    Small; 2024 Aug; 20(35):e2401631. PubMed ID: 38693099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Versatile Nanovaccine Enhancement Strategy Based on Suction-Inspired Physical Therapy.
    Wu J; Feng Y; Guo X; Meng M; Li H; Fang H; Li Z; Lin L; Guo Z; Chen J; Tian H; Chen X
    ACS Nano; 2024 Feb; 18(6):4957-4971. PubMed ID: 38288709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine.
    Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L
    Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
    Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
    J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-penetrating Peptide-mediated Nanovaccine Delivery.
    Jiang J
    Curr Drug Targets; 2021; 22(8):896-912. PubMed ID: 33538670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multimodal stratified imaging of nanovaccines in lymph nodes for improving cancer immunotherapy.
    Tian R; Ke C; Rao L; Lau J; Chen X
    Adv Drug Deliv Rev; 2020; 161-162():145-160. PubMed ID: 32827558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
    Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
    Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unlocking the power of nanomedicine: Cell membrane-derived biomimetic cancer nanovaccines for cancer treatment.
    Zhao G; Wang S; Nie G; Li N
    Med; 2024 Jul; 5(7):660-688. PubMed ID: 38582088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
    Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
    ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic nanovaccines for immunotherapy.
    Luo M; Samandi LZ; Wang Z; Chen ZJ; Gao J
    J Control Release; 2017 Oct; 263():200-210. PubMed ID: 28336379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanobiomaterial-based vaccination immunotherapy of cancer.
    Chen F; Wang Y; Gao J; Saeed M; Li T; Wang W; Yu H
    Biomaterials; 2021 Mar; 270():120709. PubMed ID: 33581608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metal-Phenolic Network-Encapsulated Nanovaccine with pH and Reduction Dual Responsiveness for Enhanced Cancer Immunotherapy.
    Zhou X; Su Q; Zhao H; Cao X; Yang Y; Xue W
    Mol Pharm; 2020 Dec; 17(12):4603-4615. PubMed ID: 33175556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Visible Codelivery Nanovaccine of Antigen and Adjuvant with Self-Carrier for Cancer Immunotherapy.
    Dong X; Liang J; Yang A; Qian Z; Kong D; Lv F
    ACS Appl Mater Interfaces; 2019 Feb; 11(5):4876-4888. PubMed ID: 30628437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimuli-Responsive Polymeric Nanovaccines Toward Next-Generation Immunotherapy.
    Mao L; Ma P; Luo X; Cheng H; Wang Z; Ye E; Loh XJ; Wu YL; Li Z
    ACS Nano; 2023 Jun; 17(11):9826-9849. PubMed ID: 37207347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antigen-Directed Fabrication of a Multifunctional Nanovaccine with Ultrahigh Antigen Loading Efficiency for Tumor Photothermal-Immunotherapy.
    Pan J; Wang Y; Zhang C; Wang X; Wang H; Wang J; Yuan Y; Wang X; Zhang X; Yu C; Sun SK; Yan XP
    Adv Mater; 2018 Feb; 30(8):. PubMed ID: 29318677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dendritic cell-based nanovaccines for cancer immunotherapy.
    Paulis LE; Mandal S; Kreutz M; Figdor CG
    Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.
    Xu Q; Fang M; Zhu J; Dong H; Cao J; Yan L; Leonard F; Oppel F; Sudhoff H; Kaufmann AM; Albers AE; Qian X
    Int J Biol Sci; 2020; 16(14):2506-2517. PubMed ID: 32792853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy.
    Qin L; Zhang H; Zhou Y; Umeshappa CS; Gao H
    Small; 2021 Jul; 17(28):e2006000. PubMed ID: 33768693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
    Kim Y; Kang S; Shin H; Kim T; Yu B; Kim J; Yoo D; Jon S
    Angew Chem Int Ed Engl; 2020 Aug; 59(34):14628-14638. PubMed ID: 32430981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.